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Abstract 
A value of 8.8 μg/mL was measured for the intrinsic solubility of indomethacin. Evidence of a form with a 
solubility of about 77 μg/mL was also obtained. Solubility measurements were conducted using the 
CheqSol and Curve Fitting methods using a maximum pH of 9. It is also demonstrated that a published 
intrinsic solubility of 410 μg/mL was in error due to decomposition of indomethacin at pH 12. The 
decomposition of indomethacin at pH 12 was investigated. Decomposition products comprising p-
chlorobenzoic acid and 5-Methoxy-2-methyl-3-indoleacetic acid were isolated and characterised. 
Keywords: Indomethacin, solubility, CheqSol, p-chlorobenzoic acid, decomposition 
 
Introduction 
Indomethacin is a widely-used non-steroidal anti-inflammatory drug (NSAID), despite its propensity to 
cause gastric irritation and ulceration. Its structure is shown in Figure 1. Indomethacin can exist in several 
polymorphic solid forms and as an amorphous solid. Yamamoto [1] reported in 1968 that he had isolated 
three polymorphs, and with slightly different melting points. Borka [2] and Lin [3] claimed to have 
found at least four polymorphic modifications. Other authors recognise only the  and  polymorphs [4-6]. 
The polymorphism is believed to arise from different orientations between the aromatic indole and phenyl 
rings [7]. Solvates are also known to exist [2,8]. 
 
















indomethacin 1 p-chlorobenzoic acid
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One difficulty associated with the measurement of the solubility of indomethacin is that the measured 
solubility can change with over time [2,10,11], suggesting that there is conversion from one form to 
another. For example, Murdande et al. [10] found that amorphous indomethacin in aqueous solution 
changed almost completely to a mixture of the and  polymorphs over a 40-minute period, with solubility 
decreasing from about 26 μg/mL to about 9 μg/mL. 
Numerous measurements of the aqueous solubility of indomethacin have been reported and results are 
presented in Table 1.  Predicted indomethacin solubilities from a number of commercial and free-to-use 
software programs are also summarised in Table 1.  
It can be seen from Table 1 that the published solubilities for the  and  polymorphs are quite 
consistent. It is, however, difficult to say with assurance whether the so-called polymorph I is the or  
polymorph, and polymorphs II and IV are not obviously either or . 
 
Table 1. Reported measured values for the solubility of indomethacin, and a selection of values calculated by 
commercial software. RT = room temperature; n/a = not available. 
 
Because amorphous solids do not have crystal lattices in which molecules can be held strongly, they are 
more soluble and are lower-melting than are their crystalline forms. Murdande et al. [10] reported that the 
aqueous solubility ratio (amorphous/-polymorph) for indomethacin was 4.9. Borka [2] found the 
amorphous form of indomethacin to have a melting point of 55-57 °C, in contrast to values ranging from 
134 to 160 °C for various polymorphic forms.   
There is considerable variation among the unspecified form solubilities reported, which could indicate 
that different proportions of polymorphs and amorphous form have contributed to the reported 
solubilities.  
One reported solubility value, (410 μg/mL), is significantly higher than all the others and has been the 
source of some controversy [23]. This result was one of 132 measured by the Sirius CheqSol method and 
cited in the Cambridge Solubility Challenge.  The Cambridge Solubility Challenge invited readers to use 100 
measured solubility values to train software for predicting solubility from the structure alone [24], and then 
Form μg/mL Temp. °C REF. Form μg/mL Temp. °C REF. Form μg/mL REF.
polymorph I 4.2 25 2 unspecified 9.5 RT 15 unspecified 17.3 39
polymorph II 15.6 25 2 unspecified 0.94 25 16 "Native" 39.1 39
polymorph IV 20 25 2 unspecified 18.5 25 17 unspecified 0.94 40
α polymorph 8.7 35 4 unspecified 25.3 35 17 unspecified 4.3 41
γ polymorph 6.9 35 4 unspecified 3.9 25 18 unspecified 2.4 42
γ polymorph 5 25 9 unspecified 2.3 25 19 unspecified 3.1 43
amorphous 22.5 25 9 unspecified 40 25 20 unspecified 0.81 44
γ polymorph 5 25 10 unspecified 15 25 21
amorphous 24.5 25 10 unspecified 27.1 RT 22
α polymorph 9.4 35 12 unspecified 410 25 25
γ polymorph 6.9 35 12 unspecified 0.94 25 31
polymorph I 9.1 25 13 unspecified 1.16 25 35
polymorph II 14.4 25 13 unspecified 3.09 25 36
α polymorph 4 n/a 14 unspecified 0.4 25 37
γ polymorph 6 n/a 14 unspecified <1 RT 38
amorphous 10 n/a 14
Measured values Calculated values
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to use the trained software to predict the solubility of a further 32 molecules whose solubilities had been 
withheld from the publication. One of these 32 molecules was indomethacin. A total of 99 entries were 
received from software providers, and the results were reviewed in a subsequent publication [25]. 
Although most of the 32 values were predicted well, software was not able to predict the solubility of 
indomethacin.   
In the current paper we used the CheqSol approach to reinvestigate the aqueous solubility of 
indomethacin and determined a value of 8.8 μg/mL. We also found evidence suggesting an amorphous 
form, as well as evidence to suggest that indomethacin might have decomposed during the measurement 
reported in [25]. We used NMR and HPLC to characterise the decomposition, which occurs at high pH. The 
results reported in this paper together with the graphical representations of dissolution and precipitation 
events during the experiments enable us to gain improved understanding of the solubility of indomethacin. 
 
Experimental 
Indomethacin (I7378, ≥99 %) was purchased from Sigma Life Science and used without further 
purification. The polymorphic form of this material was not specified. Solubility and pKa values were 
measured using the SiriusT3 automatic titration system (Sirius Analytical Ltd., Forest Row, UK), using the 
software supplied with the instrument to calculate results from the experimental data. Solubility 
experiments to prepare solid material for HPLC and NMR studies were undertaken on the Sirius GLpKa 
automatic titration system. Solution and solid composition were investigated using NMR spectroscopy, 
LCMS and HPLC with UV detection. NMR spectral data (500 MHz 1H NMR and 125 MHz 13C) were recorded 
in a BRUKER Avance 500 MHz BroadBand. 1H and 13C NMR chemical shifts are reported in parts per million 
(ppm) and referenced relative to their residual solvent peaks. Assignments were determined by 
unambiguous chemical shift, analogue comparison, coupling patterns, or HMQC experiments. LCMS data 
were collected with a Waters ZQ Mass Spectrometer using Electrospray Ionisation, connected to a Waters 
2795 HPLC and 996 DAD. The column used was an Agilent Poroshell 120 C-18 4.6 x 30 mm, 2.7 µm particle 
size, and the solvent mixtures were A: 10 mM ammonium acetate with 0.1 % formic acid, and B: 95 % 
aqueous acetonitrile with 0.05 % formic acid. HPLC/UV data were collected with a Shimadzu SPD M-20A 
PDA connected to a Shimadzu LC-10 HPLC. The column used was a Phenomenex KinetexC-18 4.6 x 50 mm, 
2.6 µm particle size, and the solvent mixtures were A: 0.1 % formic acid, and B: acetonitrile. 
Solubility measurements were carried out using the CheqSol and Curve Fitting methods. These methods 
and the associated Bjerrum Curves are described in detail elsewhere [26-28].  Indomethacin samples of 
around 2 mg were weighed accurately into glass vials. Measurements were performed in 1.5 mL of 
deionised water. The pH of the prepared sample was raised by adding standardised 0.5 M KOH solution, 
under which conditions all the indomethacin dissolved in ionised form. The transmission of light through 
the sample was monitored at 500 nm by use of a spectroscopic dip probe connected to a diode array 
spectrophotometer. The spectroscopic data were used to detect the onset of precipitation as the pH was 
lowered by adding standardised 0.5 M HCl solution. In CheqSol assays, small aliquots of KOH or HCl solution 
were added after precipitation to maintain the system close to equilibrium, and solubility results were 
calculated from rates of pH change vs. concentration. In Curve Fitting assays, only HCl was added, and 
solubility was calculated by fitting a Precipitation Bjerrum Curve to the data. Some Curve Fitting 
experiments commenced at low pH; these are discussed later. 
In order to calculate solubility results from the CheqSol and Curve Fitting data the pKa of indomethacin is 
required, and a value of 4.13 ± 0.018, I = 0.058M, 25.2 °C was measured in triplicate by a UV-metric method 
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on the same instrument. Some comment is required on this pKa measurement. A pH-metric titration 
method is often chosen to measure the pKa of compounds in which the ionisable group shows weak UV 
activity. However it proved to be surprisingly difficult to measure the pKa reliably by the pH-metric method. 
Because of its low aqueous solubility, indomethacin pKa must be measured in cosolvent-water mixtures and 
an aqueous result obtained by extrapolation. This was first attempted in methanol-water solutions adjusted 
to an ionic strength of 0.15M with KCl. A result of 4.20 was obtained from the Yasuda-Shedlovsky 
extrapolation of four psKa values measured at methanol percentages between 37.4 % and 52.7 %. However 
a further 14 methanol-water psKa values were considered to be too unreliable to include in the 
extrapolation, and confidence in the methanol-water result was low. Measurement was then attempted in 
solutions containing dioxane-water adjusted to an ionic strength of 0.15 M with KCl. A result of 4.22 was 
obtained from the Yasuda-Shedlovsky extrapolation of seven psKa values measured at dioxane percentages 
between 37.4 % and 52.7 %. This value was used in the Curve Fitting solubility measurement made from 
low to high pH (Figure 2). However the linear extrapolation of the same data yielded a result of 3.60 and 
the discrepancies between these two dioxane-water extrapolations led to some caution. It has been 
reported that indomethacin can self-aggregate in pure water and in the absence of ionic strength [29], and 
it seems likely that this tendency will be stronger at high ionic strength. This tendency for aggregation was 
not allowed for in the software used in the SiriusT3 to calculate pKa values from titration data, and this 
could lead to errors in pKa measurement. The behaviour of indomethacin during pH-metric pKa 
measurement at 1 mM concentration when forming aggregates in the presence of 0.15 M KCl and varying 
percentages of solvent is likely to be hard to predict.  The difficulty of accounting for aggregation might also 
explain why other reported measurements of indomethacin pKa differ considerably (4.01 +/-0.09, I=0.05 M, 
25 °C, CE procedure [30]), (4.17, I=0.5 M, 25 °C [31], (4.5, conditions not described [29]). The effects of 
aggregation should be less apparent in UV-metric pKa measurement, where the sample concentration is 
around 30 μM.  
In parallel with these attempts to measure indomethacin pKa by pH-metric titration it was observed 
during the solubility measurements that indomethacin did not fully dissolve at pH 9 in the presence of 0.15 
M KCl, which would be the case if the potassium salt of indomethacin was poorly soluble. It is important in 
CheqSol experiments that the sample is fully dissolved in ionised form at the start of the experiment and 
that no precipitated salt is present [26]. It was found that indomethacin did dissolve when solutions were 
prepared in deionised water adjusted to pH 9, and the subsequent solubility measurements were therefore 
done in a low ionic strength background.  
In order that the pKa value used in the solubility data sets were collected under similar conditions, it was 
measured in pH-adjusted deionised water (average ionic strength = 0.058M) by a UV-metric method. The 
carboxylic acid in indomethacin is not part of a chromophore but a small change in absorbance vs. pH was 
observed, and this was sufficient for reliable measurements to be made.  
It is understood that pH-metric experiments done at low ionic strength are susceptible to pH electrode 
calibration errors but these errors are most apparent at pH below 3 and above 11, and will have little effect 
on the solubility measurements reported here in which all relevant data were between pH 4 and 9. 
Results and Discussion 
Evaluating the outlying published result 
The starting point for this research was to discover why a value of 410 μg/mL for solubility measured by 
CheqSol was so different from other reported values. 
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 The first step was to re-examine the data from which this result was derived. This experiment used a 
standard template for measurement of solubility of a monoprotic weak acid, which includes a dissolution 
phase wherein the sample solution is held at pH 12 for several minutes. The sample will be fully ionised at 
this pH and is expected to dissolve in aqueous solution. Although an experiment starting at lower pH (e.g. 
between 7 and 10) would similarly ensure the compound is fully ionised, a value of 12 is normally chosen 
because water has a high buffer capacity at this pH and therefore resists the sample’s tendency to drag the 
pH down as it dissolves, helping to ensure complete dissolution of the sample.  The existence of titration 
data between the pH of sample dissolution and the pH of precipitation generally improves the quality of 
CheqSol experiments because it aids the calculation of acidity error and concentration factor, and may in 
some circumstances provide experimental verification of the sample’s pKa.  
A Curve Fitting experiment was then run at 25 °C in 0.15 M KCl solution on the SiriusT3, starting at low 
pH where the indomethacin was present as a suspension of crystalline solid as obtained from the 
manufacturer. The suspension was titrated slowly with KOH solution and a Precipitation Bjerrum Curve was 
calculated from the pH measured as the sample dissolved (Figure 2). Although the data below pH 3 deviates 
above a mean molecular charge of 0 and may indicate an electrode calibration error, this deviation occurs 
in a region where the sample is not undergoing ionization, and has no effect on the data above pH 3. It is, 
however significant that unionised indomethacin is poorly wettable and tends to float, which led to variable 
data quality. A result of 3.3 μg/mL was determined from the data points between the vertical red lines by 
the Curve Fitting procedure described below in the section “Investigating the intrinsic solubility of 
indomethacin”; this value is close to the values listed in Table 1.  
 
Figure 2. Curve Fitting experiment to determine the solubility of indomethacin; 3.8 mg of indomethacin in 1.5 mL 
of 0.15 M KCl, titrated with 0.5 M KOH at 25 °C. The solid blue triangles denote data points that are included in the 
Curve Fitting calculation. Unfilled triangles are excluded. 
 
The comparison of solubilities measured in two experiments done in opposite pH directions provides a 
quick way to check for metastable behaviour of the solid state after precipitation. However a solubility of 
410 μg/mL seemed too high to represent the solubility of a polymorphic form of indomethacin. Subsequent 
analysis of the data from the “410  μg/mL” experiment indicated that the sample chased equilibrium during 
the assay, indicating that this result is not likely to correspond to an amorphous form. 
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A careful literature search revealed that indomethacin can undergo base-catalysed hydrolysis [32] and it 
is shown here that it rapidly decomposes at pH 12 to p­chlorobenzoic acid and 5-methoxy-2-methyl-3-
indoleacetic acid (1). It is therefore likely that the result of 410 μg/mL is erroneous, and that the species 
that was observed to chase equilibrium during the CheqSol assay was the least soluble of these two 
decomposition products. This decomposition is illustrated in Figure 1. 
The experimental work now proceeded in two stages: a study to investigate the decomposition of 
indomethacin and a series of new CheqSol experiments to re-investigate the intrinsic solubility of 
indomethacin. 
 
Investigating the decomposition of indomethacin at high pH 
The “410 μg/mL” solubility experiment was repeated using the Sirius GLpKa, which provides 15 mL of 
solution containing 20 mg of solid for examination. NMR shows the presence of peaks representing p-
chlorobenzoic acid and the substituted indole (1). Separation of these two compounds was attempted using 
column chromatography but did not succeed due to the high polarity of the compounds. Instead, methyl 
esters of the acids were formed and separation via column chromatography was successful. The ester of 
the indole product was subsequently hydrolysed back to the corresponding acid. These compounds were 
fully characterized, and it was found that indomethacin had decomposed into p-chlorobenzoic acid and the 
substituted indole (1) during the dissolution phase of the experiment (15 – 20 min). 
The pKa values of p-chlorobenzoic acid (3.75) and the substituted indole 1 (4.42) were measured. For an 
experiment at 10 mM concentration, no precipitate was found for the indole (1), and its kinetic solubility 
was therefore expected to be higher than 10 mM. Using the measured value for the pKa of p-chlorobenzoic 
acid, the initial indomethacin decomposition CheqSol experiment was reanalysed and an accurate value for 
the solubility of p-chlorobenzoic acid was determined (302 μM; 42.4 μg/mL). This was possible because the 
indole (1) has a much higher solubility than the concentration present in the experiment. The nature of the 
precipitate was established as p-chlorobenzoic acid. Details of the decomposition study and NMR results 
are given in the Appendix. 
A re-analysis of the Bjerrum titration curve of the “410 µg/mL” experiment leads to a conclusion that is 
consistent with the hypothesis that decomposition had occurred. Figure 3 shows that twice as many 
protons were lost from the added acid as was expected. This arises from the fact that twice as much base 
has been added as would be necessary for the concentration of monoprotic indomethacin introduced in 
the experiment, thus suggesting that two acidic protons are present for each sample molecule.  If the 
calculation is modified to account for the presence of two weak acids, namely the poorly soluble p-
chlorobenzoic acid that precipitated and the substituted indole (1) that remained in solution, then the 
calculated curve representing p-chlorobenzoic acid fits the experimental one (Figure 4). 




Figure 3. CheqSol solubility Bjerrum curve for indomethacin starting from pH 12. The blue star indicates the starting 
point of the titration. The pink circle indicates the onset of precipitation. The Mean molecular charge value of -2 is 
consistent with the presence of two titratable acids. 
 
 
Figure 4. CheqSol solubility Bjerrum curve for indomethacin starting from pH 12. The settings were modified into an 
assay for p-chlorobenzoic acid in the presence of one equivalent of the substituted indole 1. Using these settings, a 
solubility result showing good agreement with the reported intrinsic solubility of p­chlorobenzoic acid was obtained. 
 
Investigating the intrinsic solubility of indomethacin  
A new series of CheqSol and Curve Fitting experiments was conducted to investigate the intrinsic 
solubility of indomethacin. To check for stability, solutions of indomethacin were prepared at pH 7.4, 9, 12 
and >12 and stored for 3 hours, and then compared by HPLC/UV. Sharp peaks after 4.2 minutes were 
observed for the solutions at pH 7.4 and 9. However the peaks occurred after 2.8 minutes for the solutions 
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composition of the solutions prepared at lower pH. With this evidence it was decided that decomposition 
could be avoided if experiments started at a pH of about 9. 
All experiments were conducted at 25 ± 0.5 °C. Samples of indomethacin between 2±0.3 mg were 
weighed into glass vials. 50 μL of DMSO was added manually to aid dissolution and the vials were then 
placed on the Sirius T3 instrument, which added 1.5 mL of deionised water and then raised the pH to 
between 9.03 and 9.39 by adding about 10 μL of 0.5 M KOH solution. In our experience the inclusion of 50 
µL DMSO in the sample solution (corresponding to a DMSO concentration of about 2 % v/v) does not alter 
significantly the measured solubility values of most compounds. The vial plus contents was then sonicated 
for 5 minutes to ensure complete dissolution of the indomethacin in ionised form. The solution was then 
titrated with 0.5 M HCl until the onset of precipitation, which was detected by an in-situ UV probe. The 
concentration of neutral indomethacin in solution at the onset of precipitation is referred to as the kinetic 
solubility. After precipitation the experiments followed CheqSol or Curve Fitting protocols, which are 
described elsewhere [28]. Results of these solubility measurements are listed in Table 2. 
 
Table 2. Results of experiments to measure solubility of indomethacin. Log S refers to the logarithm to base 10 of the 
solubility in units of molarity. 
 
 
The system chased equilibrium during the latter stages of all CheqSol experiments, suggesting that the 
precipitated material had crystallized. In one Cheqsol experiment, a few crystals of the original solid were 
added after the system had begun chasing equilibrium but there was no obvious shift in solubility, 
suggesting that the system was measuring the same polymorphic form.  
In all of the CheqSol experiments the indomethacin precipitated initially in a form with mean kinetic 
solubility of 77 μg/mL that endured for between 5 and 15 minutes before converting to a form with mean 
intrinsic solubility of 8.8 μg/mL (n = 4). By analogy with published studies [33] it is likely that the initial 
precipitation is a Liquid-Liquid Phase Separation (LLPS) in which a disordered amorphous solid state is 
created that later crystallizes. This process is summarised in Figures 5 and 6. Although the value of 8.8 
μg/mL was reproducibly measured in four experiments, it is not possible to claim that it represents the 
solubility of the least soluble polymorph. The effects of possible aggregation were not modelled in the 
software. There was 50 µL of DMSO present in each experiment, which may affect the result and the crystal 
form. The Curve Fitting experiment starting at low pH with the original solid (Figure 1) determined a 
solubility of 3.3 μg/mL, and other workers have reported lower values (Table 1). It could be useful in the 
future to re-measure the solubility in experiments with longer duration (e.g. 24 hours) to check for further 
Figure Description Ionic strength pKa
log S μg/mL log S μg/mL log S μg/mL
1
Curve-Fitting, pH2 up. 
Original solid (3.8 mg) 
dissolved during 
experiment.
0.157 M 4.22 (n = 1) -5.0 3.3
5





-3.6 76.9 -4.6 8.8
Std. Dev. 0.1 8.3 0.1 1.7
7
Curve Fitting, pH9  down. 




-3.7 68.7 -3.7 79.8
Std. Dev. 0.0 5.4 0.0 5.8
8
Curve Fitting, pH9  down. 
2 mg + 50µL DMSO
0.004 M 4.13 (n = 1) -3.7 72.1 -4.4 13.2
IntrinsicKinetic Amorphous
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conversion to a less soluble form; such changes have occasionally been observed in the Sirius laboratory 
and are described in Figure 6. 
 
Figure 5. CheqSol solubility Bjerrum curve for indomethacin starting from pH 9. The blue star denotes the start of the 
experiment. The red triangles denote the addition of HCl titrant. The pink circle indicates the onset of precipitation, 
and lies on the green line representing the solubility of the initial precipitated form. 
 
 
Figure 6. Data from Figure 5 re-plotted to show the concentrations of the initial precipitated form (plateau on left 
hand side) and the crystalline form (points from 35 minutes onwards), to which a solid blue line representing the 
intrinsic solubility has been fitted. The changes in magnitude of the concentration changes associated with the lower 
plateau may indicate that crystals are consolidating by Ostwald ripening. Although not evident here, CheqSol 
experiments with other samples sometimes show concentrations dropping to a lower plateau after longer times, 
suggesting that a metastable crystalline form has converted to a more stable crystalline form. 
 
By contrast the precipitated sample persisted in the higher solubility form throughout three Curve 
Fitting experiments, as shown in Figure 7. It may be useful to speculate why the sample remained 
amorphous in the Curve Fitting experiments but crystallized in the CheqSol. In Curve Fitting experiments pH 
is adjusted in one direction only and this often allows the sample to persist in the amorphous state. In 
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CheqSol experiments, successive aliquots of acid and base are added and it is believed this may stimulate 
the onset of crystallization after a short amorphous period. Although the sample remained amorphous 
during three Curve Fitting experiments, it converted soon after precipitation in a fourth experiment to a 
less soluble form, as shown in Figure 8. It is not understood why this conversion took place. 
 
Figure 7. Curve Fitting experiment in which indomethacin persisted in a form that is probably amorphous.   
 
 
Figure 8. Curve Fitting experiment in which indomethacin converted soon after precipitation a form that is probably 
amorphous to a form with lower solubility. 
 
It is important to point out that the Sirius Curve Fitting protocol differs from the Pion pSOL method [34]. 
In the pSOL method the solubility is calculated using an approach based on mass balance expressions 
constructed from the equilibrium equations and constants which iteratively derives the concentrations of 
all species present in solution and those which have precipitated. In the Sirius Curve Fitting method, 
samples are dissolved in ionised form and the solutions are titrated with acid or base towards the pH where 
the samples are in neutral form. The solution is a user-supervised automated on-screen graphics exercise in 
which the user selects the data points to include, and a theoretical Bjerrum curve representing the 
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precipitation and calculated from the pKa and proposed solubility result is manually fitted to the selected 
data points. Data collection for Curve Fitting experiments is fast for compounds that precipitate in the 
amorphous (i.e. LLPS) form. This is because the so-called precipitation is actually a phase separation 
between an aqueous solution and a liquid or supercooled liquid phase. The pH quickly reaches a stable 
value after each addition of titrant, and the data generally fits the theoretical model well. Curve Fitting 
experiments are not suitable for compounds that quickly crystallise after precipitation because it may take 
many minutes for the pH to reach a stable value after each addition of titrant. These compounds are 
measured by the CheqSol method. Indomethacin is an unusual compound because it tends to remain in 
amorphous form during Curve Fitting experiments yet quickly converts to a crystalline form during CheqSol 
experiments. 
Conclusions 
Indomethacin decomposes rapidly at pH 12. This invalidates measurements of its solubility that involved 
any exposure to high pH conditions, and illustrates the importance of selecting appropriate assay 
conditions when analysing acid- or base-labile molecules using titration methods.  Any unexpectedly large 
mean molecular charge values should be investigated, as they may suggest the occurrence of 
decomposition.  It is shown that in some cases CheqSol assays can be carried out successfully even for pH-
unstable compounds if mild starting conditions are utilised. Indomethacin is stable at pH 9. A value of 8.8 
μg/mL for the intrinsic solubility of indomethacin was measured in experiments in which all data was 
collected at pH 9 or below; however, this result may not represent the least soluble form. These 
experiments also provided strong evidence for the existence of a form of indomethacin with a solubility of 
about 77 μg/mL, which persisted before crystallization for between 5 and 15 minutes.  
The authors would like to suggest the following topics for future research. Any one of the following 
would be interesting: to create additional software for calculating solubility results from the pH-metric 
CheqSol data that includes equilibrium expressions to describe aggregation; to run the CheqSol 
experiments for longer times in case the form with solubility of 8.8 μg/mL converts to a less soluble form; 
to examine the precipitates with a polarising light microscope or other tools to provide evidence of their 
amorphous or crystalline form; to identify a target pH at which indomethacin precipitates as the pH is 
lowered and then to run controlled supersaturation experiments at higher pH to investigate the duration of 
supersaturation and the induction time when a form change occurred. 
Who did what: Sam Judge and Louise Towes ran pKa and solubility measurements using the SiriusT3. Darren 
Matthews ran HPLC experiments to validate the sample integrity. Bruno Falcone and Jonathan Goodman 
characterised the decomposition of indomethacin and measured the pKa and solubility of p-chlorobenzoic 
acid and the substituted indole (1). John Dearden encouraged the other authors to write this paper and 
provided valuable literature searches and insights. John Comer planned the solubility investigations, created 
the Figures and wrote or edited the text. 
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Appendix 
Indomethacin decomposition experiment 
Ionic strength adjusted water (10 mL, 0.15 M KCl) was added to indomethacin (130 mg, 0.36 mmol). The 
pH was brought to 12 by addition of KOH solution (1.73 mL, 0.5 M) and the solution was stirred for 40 min 
under nitrogen. The mixture was titrated towards low pH until precipitation was detected. 
Extraction of product of decomposition experiment 
The solution was brought to pH 1 by addition of aqueous HCl (3N). The aqueous layer was extracted with 
EtOAc (3 x 25 mL). The organic layers were combined, dried over Na2SO4 and the solvent was removed in 
vacuo to afford a white solid (100 mg).  
Identification of products of decomposition experiment 
1H NMR (500 MHz, CDCl3, T = 298 K)  7.99 (2H, d, J = 8.5 Hz), 7.43 (2H, d, J = 8.5 Hz) corresponding to p-
chlorobenzoic acid. 
1H NMR (500 MHz, CDCl3, T = 298 K)  7.76 (1H, br), 7.14 (1H, d, J = 8.7 Hz), 6.98 (1H, d, J = 2.2 Hz), 6.78 
(1H, dd, J = 8.7, 2.4 Hz), 3.84 (3H, s), 3.68 (2H, s), 2.37 (3H, s) corresponding to the substituted indole (1). 
LCMS Electrospray Ionisation: calc. for [M – H]− 218.08, found 218.4; calc. for p-chlorobenzoic acid 
C7H5
35ClO2 [M – H]
− 154.99, found 155.2 (75%); calc. for p­chlorobenzoic acid C7H5
37ClO2 [M – H]
− 156.99, 
found 157.2 (25%). 
Esterification of decomposition products 
The mixture of decomposition products was dissolved in MeOH (5 mL). HCl (1 M in MeOH, 1 mL) was 
added and the mixture was heated under reflux for 3 h, stirred at room temperature overnight, and heated 
under reflux again for 3.5 h. The solvent was concentrated in vacuo. Purification by flash column 
chromatography (SiO2, 20:1 40-60 petroleum ether / EtOAc for fraction I, and 4:1 40-60 petroleum 
ether / EtOAc for fraction II) afforded methyl p-chlorobenzoate (40 mg, fraction I), and (5-methoxy-2-
methyl-indol-3-yl) acetic acid methyl ester (2) (70 mg, fraction II). 
1H NMR (500 MHz, CDCl3, T = 298 K)  7.92 (1H, s, NH), 7.07 (1H, d, J = 8.7 Hz, H7), 7.01 (1H, d, J = 2.2 Hz, 
H4), 6.78 (1H, dd, J = 8.7, 2.2 Hz, H6), 3.87 (3H, s, OMe), 3.68 (3H, s, COOMe), 3.68 (2H, s, CH2), 2.31 (3H, s, 
C2-Me). 
13C NMR (125 MHz, CDCl3, T = 298 K)  172.8 (COO), 154.1 (C-5), 133.8 (C-2/3a/7a), 130.3 (C-2/3a/7a), 
128.9 (C-2/3a/7a), 111.1 (C-7), 110.9 (C-6), 104.2 (C-3), 100.5 (C-4), 56.0 (OMe), 52.0 (COOMe), 30.3 (CH2), 
11.7 (Me). 
Hydrolysis of 2 
A mixture of 2 (640 mg, 2.75 mmol) and LiOH•H2O (1.15 g, 27.5 mmol) in 1:1 THF:water (10 mL) was 
stirred for 23 h. Aqueous HCl (3 M, 5 mL) was added and the pH was brought to 4. The solution was 
saturated with NaCl and extracted with EtOAc (3 x 25 mL). The organic fractions were combined, dried over 
Na2SO4 and concentrated in vacuo. The product was recrystallised twice from hot ethanol to afford (5-
methoxy-2-methyl-indol-3-yl) acetic acid (5-Methoxy-2-methyl-3-indoleacetic acid, 1) (98 mg). 
1H NMR (500 MHz, CDCl3, T = 298 K)  7.72 (1H, br, NH), 7.14 (1H, d, J = 8.7 Hz, H7), 6.96 (1H, d, 
J = 2.3 Hz, H4), 6.78 (1H, dd, J = 8.7, 2.4 Hz, H6), 3.84 (3H, s, OMe), 3.65 (2H, s, CH2), 2.35 (3H, s, Me).  
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1H NMR (500 MHz, CD3OD, T = 298 K)  7.11 (1H, d, J = 8.7 Hz, H7), 6.95 (1H, d, J = 2.4 Hz, H4), 6.67 (1H, 
dd, J = 8.7, 2.4 Hz, H6), 3.79 (3H, s, OMe), 3.61 (2H, s, CH2), 2.34 (3H, s, Me). 
13C NMR (125 MHz, CD3OD, T = 298 K)  176.2 (COO), 155.0 (C5), 135.0 (C2/3a/7a), 132.1 (C2/3a/7a), 
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